cyc 202 has been researched along with oxidopamine in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | cyc 202 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
| Boo, HJ; Eun, SY; Hyun, JH; Kang, HK; Kang, JH; Kang, JI; Kim, MK; Kim, SC; Park, DB; Yoo, ES | 1 |
2 other study(ies) available for cyc 202 and oxidopamine
| Article | Year |
|---|---|
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |
6-Hydroxydopamine-induced PC12 cell death is mediated by MEF2D down-regulation.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinase 5; DNA Fragmentation; Down-Regulation; JNK Mitogen-Activated Protein Kinases; MEF2 Transcription Factors; Mitogen-Activated Protein Kinases; Myogenic Regulatory Factors; Nitric Oxide; Oxidopamine; PC12 Cells; Protein Kinase Inhibitors; Purines; Rats; Roscovitine; Signal Transduction | 2011 |